Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01848990
Recruitment Status : Completed
First Posted : May 8, 2013
Results First Posted : October 29, 2014
Last Update Posted : November 7, 2018
Sponsor:
Information provided by (Responsible Party):
Halozyme Therapeutics

Brief Summary:
The primary objectives of this study are to compare the difference in glycosylated hemoglobin (HbA1c) from baseline to Month 6 using Hylenex recombinant preadministration in continuous subcutaneous insulin infusion (CSII) versus standard CSII and to evaluate the safety of Hylenex recombinant preadministration, including local tolerability, adverse events, and hypo- and hyperglycemia rates.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Drug: Commercial Hylenex® recombinant (hyaluronidase human injection) Drug: Precommercial Hylenex recombinant (hyaluronidase human injection) Drug: Insulin lispro Drug: Insulin aspart Drug: Insulin glulisine Phase 4

Detailed Description:

This Phase 4 study is designed to demonstrate noninferiority of pretreatment with Hylenex recombinant in the CSII setting to rapid-acting analog insulin alone with respect to glycemic control as assessed by changes in HbA1c in participants with Type 1 diabetes mellitus.

Total duration of study treatment is 24 months. However, according to the study design, the primary outcome measure is to be assessed at 6 months and an interim analysis is to be completed at 6 months for the secondary outcome measures and adverse events. Therefore, data reported in this clinical trials record is for the 6-month interim analysis.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 456 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)
Study Start Date : March 2013
Actual Primary Completion Date : February 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Commercial Hylenex Recombinant (Formulation 1)
Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
Drug: Commercial Hylenex® recombinant (hyaluronidase human injection)
Other Names:
  • Formulation 1
  • Hylenex
  • Recombinant human hyaluronidase (rHuPH20)

Drug: Insulin lispro
Other Names:
  • Humalog
  • Lispro

Drug: Insulin aspart
Other Names:
  • Novolog
  • Aspart

Drug: Insulin glulisine
Other Names:
  • Apidra
  • Glulisine

Experimental: Precommercial Hylenex Recombinant (Formulation 2)
Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
Drug: Precommercial Hylenex recombinant (hyaluronidase human injection)
Other Names:
  • Formulation 2
  • Hylenex
  • rHuPH20

Drug: Insulin lispro
Other Names:
  • Humalog
  • Lispro

Drug: Insulin aspart
Other Names:
  • Novolog
  • Aspart

Drug: Insulin glulisine
Other Names:
  • Apidra
  • Glulisine

Active Comparator: Standard Rapid-Acting Insulin CSII
Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
Drug: Insulin lispro
Other Names:
  • Humalog
  • Lispro

Drug: Insulin aspart
Other Names:
  • Novolog
  • Aspart

Drug: Insulin glulisine
Other Names:
  • Apidra
  • Glulisine




Primary Outcome Measures :
  1. Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline; 6 Months ]
    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

  2. Change From Baseline to 12 Months in HbA1c [ Time Frame: Baseline; 12 Months ]
    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.


Secondary Outcome Measures :
  1. Rates of Hypoglycemia Events (HE) to Month 6 [ Time Frame: After Month 1 up to Month 6 ]
    Overall rates of hypoglycemia (defined as blood glucose ≤70 milligrams per deciliter [mg/dL] and <56 mg/dL) were based on measurements after 1 month up to 6 months. A severe HE was classified as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. A nocturnal HE was classified as an event with a blood glucose of ≤70 mg/dL with start time between 2300 and 0600, inclusive. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  2. Rates of HEs to Month 12 [ Time Frame: After Month 1 up to Month 12 ]
    Overall rates of hypoglycemia (defined as blood glucose ≤70 milligrams per deciliter [mg/dL] and <56 mg/dL) were based on measurements after 1 month up to 12 months. A severe HE was classified as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. A nocturnal HE was classified as an event with a blood glucose of ≤70 mg/dL with start time between 2300 and 0600, inclusive. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  3. Rates of Hyperglycemia Events to Month 6 [ Time Frame: After Month 1 up to Month 6 ]
    Overall rates of hyperglycemia (defined as blood glucose >240 mg/dL and >300 mg/dL) were based on measurements after 1 month up to 6 months. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  4. Rates of Hyperglycemia Events to Month 12 [ Time Frame: After Month 1 up to Month 12 ]
    Overall rates of hyperglycemia (defined as blood glucose >240 mg/dL and >300 mg/dL) were based on measurements after 1 month up to 12 months. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  5. Mean Glucose Excursions at 6 Months [ Time Frame: After Month 1 up to Month 6 ]
    A 4-hour postprandial glucose excursion was measured for 3 meals after 1 month up to 6 months. For each of the 3 meals, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal (for measurements taken within 15 minutes before a meal). The average of all excursions is presented. Least Squares (LS) means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  6. Mean Glucose Excursions at 12 Months [ Time Frame: After Month 1 up to Month 12 ]
    A 4-hour postprandial glucose excursion was measured for 3 meals after 1 month up to 12 months. For each of the 3 meals, the mealtime (breakfast, lunch, and dinner) excursions were calculated as the post-meal glucose value minus the pre-meal (for measurements taken within 15 minutes before a meal). The average of all excursions is presented. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  7. Standard Deviation of Self-Monitoring Blood Glucose Values at 6 Months [ Time Frame: After Month 1 up to Month 6 ]
    Standard deviation of self-monitoring blood glucose values was calculated based on measurements taken within 15 minutes before a meal, 1 month and up to 6 months after study drug administration. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  8. Standard Deviation of Self-Monitoring Blood Glucose Values at 12 Months [ Time Frame: After Month 1 up to Month 12 ]
    Standard deviation of self-monitoring blood glucose values was calculated based on measurements taken within 15 minutes before a meal, 1 month and up to 12 months after study drug administration. LS means were calculated from ANOVA with treatment (Hylenex, standard rapid-acting insulin CSII) as a fixed effect. Comparisons were made by pooling all of the rHuPH20 pretreatment participants (including both Formulations 1 and 2) and comparing against the standard CSII treatment arm. Formulation 1 versus Formulation 2 was compared as a supportive analysis.

  9. Number of Participants Achieving HbA1c <7.0% and HbA1c ≤6.5% at Month 12 [ Time Frame: Month 12 ]
    The number of participants achieving HbA1c goals of <7% and ≤6.5% was calculated.

  10. Change From Baseline in Body Weight to Month 12 [ Time Frame: Baseline; Week 2; Months 1, 2, 3, 4, 6, 9, and 12 ]
    Baseline is defined as the last measurement prior to randomization.

  11. Average of Daily Insulin Doses (Bolus, Basal, and Total) [ Time Frame: from Randomization up to Month 12 ]
    The daily bolus insulin dose is calculated as the daily prandial (occurring before a meal) insulin dose plus the daily corrective insulin dose. Cumulative basal dosage is to generally be within 40% to 60% of the total daily dose.

  12. Average Carbohydrate Factor (CarbF) Values [ Time Frame: Month 1 to Month 12 ]
    CarbF is calculated as 2.6 * weight (pounds) / total daily dose of insulin (grams per unit).

  13. Average Correction Factor (CorrF) Values [ Time Frame: Month 1 to Month 12 ]
    CorrF is calculated as 1960 / total daily dose of insulin (milligrams/[deciliter*unit]).

  14. Average of Bolus Times Relative to Meal Times [ Time Frame: Month 1 to Month 12 ]
    The average meal bolus timing relative to meal time is defined as the minutes between the start time of a meal bolus and the start time of a meal.

  15. Average Glucose, Median Glucose, and Average Daily Standard Deviation [ Time Frame: Randomization to Month 12 ]
    For each participant, the following continuous glucose monitoring (CGM) parameters were calculated using CGM values recorded after Randomization up to Month 12: average glucose, median glucose, and average daily standard deviation.

  16. Time Per Day <56 Milligrams Per Deciliter (mg/dL), ≤70 mg/dL, >70 mg/dL, <140 mg/dL, ≥140 mg/dL, Outside of 71 to 180 mg/dL, and Outside of 71 to 139 mg/dL [ Time Frame: Randomization to Month 12 ]
    For each participant, the following CGM parameters were calculated using CGM values recorded after Randomization up to Month 12: time per day spent in the pre-defined glucose classes.

  17. Area Per Day <56 mg/dL, ≤70 mg/dL, ≥140 mg/dL, Outside of 71 to 180 mg/dL, and Outside of 71 to 139 mg/dL [ Time Frame: Randomization to Month 12 ]
    For each participant, the following continuous glucose monitoring (CGM) parameters were calculated using CGM values recorded after Randomization up to Month 12: area per day spent in the pre-defined glucose classes. The area per day for a specific glucose concentration range (e.g., <56 mg/dL) is the sum of the area under the curve with glucose concentration falling in the specific glucose concentration range (e.g., <56 mg/dL). For example, if the glucose stays constant at 50 mg/dL for the whole day (1,440 minutes), the area per day for glucose < 56 mg/dL equals: 50*1440 = 72,000 mg*minutes/dL.

  18. Change From Baseline in Weighted Impact ADDQoL Values at Month 12 [ Time Frame: Baseline; Month 12 ]
    The Audit of Diabetes Dependent Quality of Life (ADDQoL) is a validated, diabetes-specific questionnaire to evaluate the participant's assessment of quality of life (QoL). Participants rated the impact of diabetes on 19 applicable domains on a scale from -3 (maximum negative impact) to +3 (maximum positive impact) and then rated the importance of those domains for their QoL on a scale from 3 (very important) to 0 (not at all important). Impact ratings were multiplied by the corresponding importance ratings to provide a weighted-impact score for each domain from -9 (maximum negative impact) to +9 (maximum positive impact).

  19. Change From Baseline in Average Weighted Impact ADDQoL Values at Month 12 [ Time Frame: Baseline; Month 12 ]
    The ADDQoL is a validated, diabetes-specific questionnaire to evaluate the participant's assessment of QoL. Participants rated the impact of diabetes on 19 applicable domains on a scale from -3 (maximum negative impact) to +3 (maximum positive impact) and then rated the importance of those domains for their QoL on a scale from 3 (very important) to 0 (not at all important). Impact ratings were multiplied by the corresponding importance ratings to provide a weighted-impact score for each domain from -9 (maximum negative impact) to +9 (maximum positive impact). Weighted impact scores were summed and divided by the number of applicable domains to give an overall Average Weighted Impact (AWI) score (higher values represent more positive impact). If there were less than 13 non-missing weighted-impact values, AWI was not to be calculated. Baseline is defined as the last measurement prior to randomization.

  20. Change From Baseline in DTSQs and DTSQc at Month 12 [ Time Frame: Baseline; Month 12 ]
    The Diabetes Treatment Satisfaction Questionnaire-status version (DTSQs) and DTSQ-change version (DTSQc) are validated tools to assess treatment satisfaction and change in treatment satisfaction after therapy changes have occurred. The scale total was computed by adding the 6 items (1, 4, 5, 6, 7, and 8) to produce the Treatment Satisfaction scale total, which has a minimum of 0 and a maximum of 36 on the DTSQs and a minimum of -18 and a maximum of 18 on the DTSQc. Higher scores represent greater satisfaction. If any of the 6 item scores were missing and the numbers of missing scores were less than the number of non-missing scores, the Treatment Satisfaction scale score was to be computed by taking the average of the existing scores and multiplying the average by 6. If there were less than 4 non-missing item scores, the Treatment Satisfaction scale score was not to be calculated. Baseline is defined as the last measurement prior to randomization.

  21. Mean Time to Change Infusion Site [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.

  22. Mean Additional Time for Hylenex Pre-administration [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.

  23. Number of Participants With the Indicated Responses to the Question Regarding the Difficulty of Infusion Site Change [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.

  24. Number of Participants With the Indicated Responses to the Device Handling Questions [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program. Question 1: Achieve excellent post meal glucose control; Question 2: Insulin responds quickly when basal rate is changed; Question 3: Insulin responds quickly when correction bolus is given.

  25. Mean Times Per Week Participants Said They Were Eating to Avoid Going Low Due to Late Insulin Action [ Time Frame: Month 12 ]
    Participants were asked device handling questions to provide information about the impact of the Hylenex administration procedure on everyday life and to investigate perceptions of the overall efficacy and responsiveness of their insulin program.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female of age 18 years or older with a history of T1DM for at least 12 months
  2. Glycosylated hemoglobin (HbA1c) 6.5% to 9.5% (inclusive) based on central laboratory results
  3. Fasting C-peptide <0.6 nanograms per milliliter (ng/mL)
  4. Current use of an insulin pump compatible with available tubing for Hylenex recombinant infusion and use of an infusion set compatible with the tubing available or willingness to switch to an infusion set compatible with tubing available for infusion of Hylenex recombinant
  5. Current treatment at the time of screening with insulin <300 units per day (U/day)
  6. Participants who routinely use continuous glucose monitoring (CGM) (defined as average CGM use 5 or more days per week over the preceding 3 months) and those who do not routinely used CGM are both eligible for inclusion in the study. Intermittent use of CGM is also acceptable but will not be a criterion use for stratified randomization.
  7. Participants should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug infusions and assessments required in this protocol.

Exclusion Criteria:

  1. Type 2 diabetes
  2. Known or suspected allergy to any component of any of the study drugs in this study
  3. Severe proliferative retinopathy or maculopathy, and/or gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy, of such severity as to impede the participant's ability to comply with protocol procedures, as judged by the Investigator
  4. History of transmural myocardial infarction, congestive heart failure and uncontrolled hypertension (diastolic blood pressure [BP] consistently >100 millimeters of mercury [mmHg]) are exclusionary
  5. As judged by the Investigator, clinically significant active disease of the gastrointestinal, cardiovascular (including history of stroke, history of arrhythmia, or conduction delays on electrocardiogram [ECG]), hepatic, neurological, renal, genitourinary, pulmonary, or hematological systems of such severity as to impede the participant's ability to comply with protocol procedures
  6. History of any illness or disease that in the opinion of the Investigator might confound the results of the study or pose additional risk in administering the study drugs to the participant
  7. As judged by the Investigator, clinically significant findings in routine laboratory data at screening
  8. Use of drugs that may interfere with the interpretation of study results or are known to cause clinically relevant interference with hyaluronidase action, insulin action, glucose utilization, or recovery from hypoglycemia (including systemic pharmacologic corticosteroid). Use of pramlintide or a glucagon-like peptide [GLP]-1 receptor agonist is not exclusionary but participants using these agents will be subjected to stratified randomization. Use of aspirin (acetylsalicylic acid [ASA]) up to 325 milligrams (mg)/day is not exclusionary but should be noted for analysis.
  9. Hypoglycemic unawareness of such severity as to impede the participant's ability to comply with protocol procedures, as judged by the Investigator.
  10. Current addiction to alcohol or substance abuse as determined by the Investigator.
  11. Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives, and/or barrier methods). Abstinence alone is not considered an adequate contraceptive measure for the purposes of this study.
  12. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01848990


  Show 39 Study Locations
Sponsors and Collaborators
Halozyme Therapeutics
Investigators
Layout table for investigator information
Study Director: Douglas Muchmore, MD Halozyme Therapeutics

Additional Information:
Layout table for additonal information
Responsible Party: Halozyme Therapeutics
ClinicalTrials.gov Identifier: NCT01848990     History of Changes
Other Study ID Numbers: Halo-117-403
First Posted: May 8, 2013    Key Record Dates
Results First Posted: October 29, 2014
Last Update Posted: November 7, 2018
Last Verified: October 2018

Keywords provided by Halozyme Therapeutics:
Type 1 Diabetes Mellitus
Sub Cutaneous Insulin Infusion
Rapid Acting Analog Insulin
Hylenex
Halozyme
Phase 4

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Insulin, Globin Zinc
Insulin Aspart
Insulin, Long-Acting
Insulin degludec, insulin aspart drug combination
Insulin Lispro
Insulin glulisine
Hypoglycemic Agents
Physiological Effects of Drugs